ArticleMaterials today. Bio2025
Prodrug-loaded micelles targeting articular cavity reactive oxygen species for rheumatoid arthritis treatment.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydrogels-Advanced Polymer Platforms for Drug Delivery.Polymers · 2026Review
- Advancing Arthritis Therapy: The Frontier of Targeted and Responsive Nanomedicine.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress plays an important role in the pathogenesis of rheumatoid arthritis (RA). Excessive reactive oxygen species (ROS) activate the NLR family pyrin domain containing 3 (NLRP3) inflammasome, release multiple inflammatory mediators, stimulate macrophage polarization, and exacerbate the inflammatory response. In response to the pathological features of RA, we designed a dihydroartemisinin (DHA)-ROS sensitive prodrug loaded into carriers of Soluplus and Vitamin E polyethylene glycol succinate (TPGS) using a thin film hydration to expect that the nano-micelles could target for delivery to the inflammation site due to extravasation through leaky vasculature and subsequent inflammatory cell-mediated sequestration (ELVIS) effects, and the higher ROS level in articular cavity resulting in the breaking of ROS sensitive bonds and the release of anti-inflammatory DHA and antioxidant cinnamaldehyde (CA), avoiding the instability of DHA and CA circulating in the body. In addition, prodrug-carrying nanomicelles (DHA∼CA@NM) promoted the polarization of M1 to M2 macrophages, which exerted a series of anti-inflammatory effects. Intravenously injected DHA∼CA@NM could accumulate at inflamed joints of CIA rats, attenuate joint damage and bone erosion, and inhibit synovial hyperplasia and formation of pannus, thus alleviating joint inflammation and displaying high biosafety. The protective mechanism of DHA∼CA@NM may be related to the inhibition of NLRP3 inflammasome, which has the potential to be developed as a safe and effective nano-formulation for the treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.